Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 12:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 439 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: EXCRETION Clear all
Not listed No phase listed Observational

A Study Comparing Outcomes of Kidney Transplants in Patients on Steroids Versus Those Who Discontinue Steroids

NCT00273559
View directory record Official record
Conditions
Kidney Diseases
Interventions
prednisone
Drug
Lead sponsor
Florida Hospital Transplant Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 12, 2008 · Synced Oct 19, 2026, 12:33 PM EDT
Active, not recruiting Not applicable Interventional

Effect of Weight Loss on Urinary Oxalate Excretion in Obese Calcium Oxalate Kidney Stone Formers

NCT04633811
View directory record Official record
Conditions
Kidney Stone
Interventions
Low Oxalate Diet before Weight Loss, Oral load of oxalate and sucralose before Weight Loss, Optifast VLCD Program, Optifast VLCD Transition Phase, Low Oxalate Diet after Weight Loss, Oral load of oxalate and sucralose after Weight Loss
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 19, 2026, 12:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Timing of Sodium Intake and Nocturnal Sodium Excretion and Blood Pressure in Obese African Americans

NCT04021355
View directory record Official record
Conditions
Obesity, Hypertension, Circadian Dysregulation, Salt; Excess
Interventions
Oral sodium supplementation
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
25 Years to 45 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 19, 2026, 12:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants

NCT02692677
View directory record Official record
Conditions
Healthy
Interventions
JNJ-42756493
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
30 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 19, 2026, 12:33 PM EDT
Terminated Not applicable Interventional

A PHASED, PROSPECTIVE, MULTI-CENTER STUDY OF THE ELITA SYSTEM

NCT05713253
View directory record Official record
Conditions
Refractive Error
Interventions
ELITA System
Device
Lead sponsor
Johnson & Johnson Surgical Vision, Inc.
Industry
Eligibility
22 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Palo Alto, California • Draper, Utah
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 19, 2026, 12:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects

NCT03448172
View directory record Official record
Conditions
Healthy
Interventions
[14C]PF-05221304
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 19, 2026, 12:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects

NCT03748628
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
EDP-305
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 19, 2026, 12:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets

NCT02373046
View directory record Official record
Conditions
Healthy
Interventions
LX4211
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 19, 2026, 12:33 PM EDT
Recruiting Not applicable Interventional

Optimal Pulse Width Used in Transcutaneous Electrical Nerve Stimulation for Treating Nocturnal Enuresis in Children

NCT06135311
View directory record Official record
Conditions
Nocturnal Enuresis, Bedwetting
Interventions
Pulse Width 260us, Pulse Width 50us
Device
Lead sponsor
Albany Medical College
Other
Eligibility
5 Years to 17 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 19, 2026, 12:33 PM EDT
Terminated Phase 4 Interventional Results available

Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen

NCT01003249
View directory record Official record
Conditions
Overactive Bladder, Constipation, Lower Urinary Tract Symptoms
Interventions
Baclofen, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 19, 2026, 12:33 PM EDT
Withdrawn Phase 2Phase 3 Interventional

The Effect of Vitamin D on Urinary Calcium Excretion in Kidney Stone Formers With High Urinary Calcium

NCT00948740
View directory record Official record
Conditions
Vitamin D Deficiency, Nephrolithiasis
Interventions
vitamin D (ergocalciferol)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 19, 2026, 12:33 PM EDT
Completed Not applicable Interventional

Prediction of Excretion and Toxicity of High Dose Methotrexate in Children and Adolescents With ALL

NCT02133599
View directory record Official record
Conditions
ALL
Interventions
IOHEXOL
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
2 Years to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 19, 2026, 12:33 PM EDT
Terminated Phase 4 Interventional

Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study

NCT05492695
View directory record Official record
Conditions
Migraine
Interventions
Galcanezumab, Placebo
Drug · Other
Lead sponsor
Diamond Headache Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 19, 2026, 12:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How [14C]ASP0367 is Processed by the Body in Healthy Men

NCT05217901
View directory record Official record
Conditions
Healthy Volunteers
Interventions
14C-labeled ASP0367
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 19, 2026, 12:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Absorption, Metabolism and Excretion of Dietary Polyphenolic Bioactives in Humans

NCT03194620
View directory record Official record
Conditions
Healthy
Interventions
Thearubigins, Theaflavins, Procyanidin Dimer B2 (DB2), (-)-Epigallocatechin-3-O-gallate (EGCG), (-)-Epicatechin-3-O-gallate (ECG), (-)-Epicatechin (EC), (-)-Epigallocatechin (EGC), Control
Other
Lead sponsor
University of California, Davis
Other
Eligibility
25 Years to 60 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 19, 2026, 12:33 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4515100 in Healthy Male Participants

NCT07867327
View directory record Official record
Conditions
Healthy
Interventions
[¹⁴C]-LY4515100 Oral Solution, LY4515100 Tablet, [¹⁴C]-LY4515100 IV
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 19, 2026, 12:33 PM EDT
Completed Phase 1 Interventional

How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers

NCT07444268
View directory record Official record
Conditions
Advanced Hematologic Malignancies
Interventions
DSP-5336, [14C]-DSP-5336
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 19, 2026, 12:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects

NCT00823745
View directory record Official record
Conditions
HCV
Interventions
[14C]-PF-00868554
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 9, 2009 · Synced Oct 19, 2026, 12:33 PM EDT
Completed Not applicable Interventional Results available

The Immune Directed Individualized Elimination Therapy (iDIET) Study

NCT05543512
View directory record Official record
Conditions
Eosinophilic Esophagitis, EoE
Interventions
Algorithm to diagnose food allergens, Sham diet
Device · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 19, 2026, 12:33 PM EDT
Completed Not applicable Interventional Results available

Study of Dietary Additive Phosphorus on Proteinuria and Fibroblast Growth Factor-23

NCT02020785
View directory record Official record
Conditions
Albuminuria
Interventions
Higher phosphorus period, Lower phosphorus period
Other
Lead sponsor
Geisinger Clinic
Other
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 19, 2026, 12:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Oxalobacter Formigenes Colonization and Urinary Oxalate Excretion

NCT03752684
View directory record Official record
Conditions
Calcium Oxalate Urolithiasis
Interventions
Moderately high oxalate/low calcium diet non-colonized, Oxalobacter formigenes, Moderately high oxalate/low calcium diet colonized
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 19, 2026, 12:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Calderasib (MK-1084) Human Absorption, Distribution, Metabolism, and Excretion in Healthy Adult Participants (MK-1084-006)

NCT06687759
View directory record Official record
Conditions
Healthy
Interventions
[14C]Calderasib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 19, 2026, 12:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Utilization of the Community Popular Opinion Leader (C-POL) Model in Alabama

NCT00260754
View directory record Official record
Conditions
Risk Behavior, Sexually Transmitted Diseases
Interventions
Community-Popular Opinion Leader Model, Diffusion of Innovations
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 31, 2006 · Synced Oct 19, 2026, 12:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label, Single-dose, Non-randomized Study of IV 14C-labeled PER977 in Healthy Male Subjects

NCT02205905
View directory record Official record
Conditions
Healthy
Interventions
14C PER977
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
15 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Oct 19, 2026, 12:33 PM EDT